Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2022.2113252
Abstract: Abstract Objective To model changes in prices, utilization, and expenditures of targeted immune modulators (TIMs) for rheumatoid arthritis, accounting for biosimilar entry. Methods Using IQVIA National Sales Perspective data between 2013 and 2019, we examined… read more here.
Keywords: entry; targeted immune; immune modulators; exclusivity milestones ... See more keywords